Patterns of recurrence of early breast cancer according to estrogen receptor status: A therapeutic target for a quarter of a century

Breast Cancer Research and Treatment

Volumn 117, Issue 2, 2009, Pages 319-324

  Pagani, Olivia ^a   Price, Karen N ^c   Gelber, Richard D ^c   Castiglione Gertsch, Monica ^d   Holmberg, Stig B ^e   Lindtner, Jurij ^f   Thürlimann, Beat ^b,g   Collins, John ^h   Fey, Martin F ^b,i   Coates, Alan S ^j,k   Goldhirsch, Aron ^a,l  

^a ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

^b SWISS GROUP FOR CLINICAL CANCER RESEARCH SAKK   (Switzerland)

^c FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^d IBCSG Coordinating Center   (Switzerland)

^e SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^f INSTITUTE OF ONCOLOGY   (Slovenia)

^g Senology Center of Eastern Switzerland   (Switzerland)

^h ROYAL MELBOURNE HOSPITAL   (Australia)

ⁱ UNIVERSITY OF BERN   (Switzerland)

^j International Breast Cancer Study Group   (Switzerland)

^k UNIVERSITY OF SYDNEY   (Australia)

^l EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

more..

Author keywords

Breast cancer; Chemotherapy; Estrogen receptor; Hormonal therapy

Indexed keywords

CYCLOPHOSPHAMIDE; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; PREDNISONE; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RECURRENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG TREATMENT FAILURE; EARLY CANCER; FEMALE; FOLLOW UP; HUMAN; LOW DRUG DOSE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; NEOPLASM RECURRENCE, LOCAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, ESTROGEN; TREATMENT OUTCOME;

EID: 68949122990     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-008-0282-0     Document Type: Article

References (23)

1. A Goldhirsch W Wood R Gelber 2007 Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer Ann Oncol 18 1133 1144 10.1093/annonc/mdm271
2. DT Zava A Wyler-Von Ballmoos A Goldhirsch 1982 A quality control study to assess the inter-laboratory variability of routine estrogen and progesterone receptor assays Eur J Cancer Clin Oncol 18 713 721 10.1016/0277-5379(82)90068-2
3. VC Jordan DT Zava U Eppenberger 1983 Reliability of steroid hormone receptor assays: an international study Eur J Cancer Clin Oncol 19 357 363 10.1016/0277-5379(83)90133-5
4. A Goldhirsch AS Coates RD Gelber 2006 First select the target: better choice of adjuvant treatments for breast cancer patients Ann Oncol 17 1772 1776 10.1093/annonc/mdl398
5. Early Breast Cancer Trialists' Collaborative Group 2005 Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 1687 1717 10.1016/S0140-6736(05)66544-0
6. Ludwig Breast Cancer Study Group 1984 Randomized trial of chemoendocrine therapy, endocrine therapy, and mastectomy alone in postmenopausal patients with operable breast cancer and axillary node metastasis Lancet 1 1256 1260
7. A Goldhirsch RD Gelber RJ Simes 1989 Costs and benefits of adjuvant therapy in breast cancer: a quality-adjusted survival analysis J Clin Oncol 7 36 44
8. M Castiglione RD Gelber A Goldhirsch 1990 Adjuvant systemic therapy for breast cancer in the elderly: competing causes of mortality J Clin Oncol 8 519 526
9. M Castiglione-Gertsch C Johnsen A Goldhirsch 1994 The International (Ludwig) Breast Cancer Study Group Trials I-IV: 15 years follow-up Ann Oncol 5 717 724
10. D Crivellari K Price RD Gelber 2003 Adjuvant endocrine therapy compared with no systemic therapy for elderly women with early breast cancer: 21-year results of International Breast Cancer Study Group Trial IV J Clin Oncol 21 4517 4523 10.1200/JCO.2003.03.559
11. EL Kaplan P Meier 1958 Nonparametric estimation from incomplete observations J Am Stat Assoc 53 457 481 10.2307/2281868
12. RJ Gray 1988 A class of k-sample tests for comparing the cumulative incidence of a competing risk Ann Stat 16 1141 1154 10.1214/aos/1176350951
13. Kalbfleisch JD, Prentice RL (1980) The statistical analysis of failure time data. Wiley, New York, p 169
14. T Saphner DC Tormey R Gray 1996 Annual hazard rates of recurrence for breast cancer after primary therapy J Clin Oncol 14 2738 2746
15. P Goss AL Allan DI Rodenhiser 2008 New clinical and experimental approaches for studying tumour dormancy: does tumour dormancy offer a therapeutic target? APMIS 116 552 568
16. KM Clough-Gorr AK Fink RA Silliman 2008 Challenges associated with longitudinal survivorship research: attrition and a novel approach of reenrollment in a 6-year follow-up study of older breast cancer survivors J Cancer Surviv 2 2 95 103 10.1007/s11764-008-0049-y
17. T Cufer 2007 Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women Ann Oncol Suppl 8 viii8 viii17
18. RF Swaby VC Jordan 2008 Low-dose estrogen therapy to reverse acquired antihormonal resistance in the treatment of breast cancer Clin Breast Cancer 8 2 124 133 10.3816/CBC.2008.n.012
19. DA Berry C Cirrincione IC Henderson 2006 Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer JAMA 295 1658 1667 10.1001/jama.295.14.1658
20. Albain K, Barlow W, O'Malley F et al (2004) Mature outcomes and new biologic correlates on phase III Intergroup trial 0100 (INT-0100, SWOG-8814): concurrent (CAFT) vs sequential (CAF-T) chemohormonal therapy (cyclophosphamide, doxorubicin, 5-fluorouracil, tamoxifen) vs T alone for postmenopausal, node positive, estrogen (ER) and/or progesterone PgR receptor-positive breast cancer. Proc San Antonio Breast Cancer Symposium, 2004 (Abstr 37)
21. A Hamilton G Hortobagyi 2005 Chemotherapy: what progress in the last 5 years? J Clin Oncol 23 1760 1775 10.1200/JCO.2005.10.034
22. Breast International Group MINDACT (Microarray In Node negative Disease may Avoid Chemotherapy) trial. http://www.breastinternationalgroup.org/TransBIG/ Mindact.aspx. Accessed October 3, 2008
23. National Cancer Institute US National Institutes of Health. The TAILORx Breast Cancer Trial. http://www.cancer.gov/clinicaltrials/digestpage/TAILORx. Accessed October 3, 2008